By Michael Gwarisa The U.S. Food and Drug Administration (FDA) has approved a new formulation of the HIV medicine dolutegravir for use in newborns from birth through four weeks of age, expanding treatment options for one of the most vulnerable groups at risk of HIV infection. The approval covers Tivicay PD tablets for oral suspension
Read More
By Michael Gwarisa Zimbabwe is among the countries hardest hit by recent disruptions to the United States President’s Emergency Plan for AIDS Relief (PEPFAR), with new data released ahead of the International AIDS Society (IAS) Conference on HIV Science (AIDS 2026) showing that more than 6,000 fewer children were receiving PEPFAR-supported HIV treatment by the
Read More
By Michael Gwarisa A once-weekly pill for HIV treatment has performed as well as standard daily therapy in two landmark Phase III clinical trials, bringing researchers a step closer to offering people living with HIV the world’s first complete once-weekly oral treatment regimen. The findings from the ISLEND-1 and ISLEND-2 studies will be presented at
Read More
By Michael Gwarisa Nearly seven in ten Zimbabweans who previously used daily oral HIV prevention pills abandoned treatment because of the burden of taking medication every day, a new survey has revealed, adding fresh evidence that long-acting injectable HIV prevention could transform the country’s fight against new HIV infections. The findings come just months after
Read More
By Michael Gwarisa Malawi has received its first shipment of lenacapavir, a long-acting injectable HIV prevention medicine, with enough doses expected to protect 38,000 people, marking another milestone in Africa’s rollout of one of the most significant advances in HIV prevention in decades. The arrival of the first of two planned shipments positions Malawi as
Read More
By Michael Gwarisa A groundbreaking Zimbabwean study has revealed that older people living with HIV have significantly poorer bone health than their HIV-negative peers, with women facing an even greater risk of developing osteoporosis and suffering debilitating fractures as they age. Published in the Journal of Bone and Mineral Research, the study found that HIV
Read More
Kuda Pembere in Bulawayo Bulawayo Metropolitan Province recorded strong uptake of Voluntary Medical Male Circumcision (VMMC) in 2024, with the highest coverage achieved among males aged 25 to 29 and 15 to 19 years, according to the National AIDS Council (NAC). VMMC remains one of Zimbabwe’s key HIV prevention strategies, with studies showing that medical
Read More
Kuda Pembere in Bulawayo A rise in sexually transmitted infections (STIs) among young people aged between 10 and 24 years is prompting the National AIDS Council (NAC) to intensify HIV prevention programmes in Magwegwe District, one of Bulawayo’s areas with identified HIV hotspots. For NAC programming purposes, Magwegwe District encompasses Magwegwe, Pumula and Lobengula suburbs
Read More
Kuda Pembere in Bulawayo Mawaba Primary School says it is determined to preserve the gains achieved through the DREAMS programme, including a dramatic reduction in child sexual abuse cases, despite the suspension of funding for the initiative. School authorities say the programme helped establish a Gender-Based Violence (GBV) room and strengthened child protection systems, contributing
Read More